These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 20197621

  • 1. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
    Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP.
    J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
    [Abstract] [Full Text] [Related]

  • 2. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo.
    Parisotto M, Grelet E, El Bizri R, Dai Y, Terzic J, Eckert D, Gargowitsch L, Bornert JM, Metzger D.
    J Exp Med; 2018 Jun 04; 215(6):1749-1763. PubMed ID: 29743291
    [Abstract] [Full Text] [Related]

  • 3. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
    Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP.
    Sci Signal; 2009 Aug 18; 2(84):ra44. PubMed ID: 19690330
    [Abstract] [Full Text] [Related]

  • 4. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
    Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP.
    Nature; 2005 Aug 04; 436(7051):725-30. PubMed ID: 16079851
    [Abstract] [Full Text] [Related]

  • 5. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR, Tripathi P, Hsi AC, Ning J, Ruzinova MB, Liapis H, Bailey M, Zhang H, Maher CA, Humphrey PA, Andriole GL, Ding L, You Z, Chen F.
    Oncogene; 2016 Jun 23; 35(25):3282-92. PubMed ID: 26477312
    [Abstract] [Full Text] [Related]

  • 6. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
    Jung SH, Hwang HJ, Kang D, Park HA, Lee HC, Jeong D, Lee K, Park HJ, Ko YG, Lee JS.
    Oncogene; 2019 Mar 23; 38(10):1639-1650. PubMed ID: 30337688
    [Abstract] [Full Text] [Related]

  • 7. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression.
    Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H.
    Mol Cell Biol; 2008 May 23; 28(10):3281-9. PubMed ID: 18332125
    [Abstract] [Full Text] [Related]

  • 8. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L, Guo X, Wang J, Jiang C, Bosland MC, Lü J, Deng Y.
    Cancer Prev Res (Phila); 2016 Jan 23; 9(1):35-42. PubMed ID: 26511486
    [Abstract] [Full Text] [Related]

  • 9. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, Aufinger A, Limberger T, Trachtova K, Kodajova P, Högler S, Schlederer M, Stoiber S, Oberhuber M, Bolis M, Neubauer HA, Miranda S, Tomberger M, Harbusch NS, Garces de Los Fayos Alonso I, Sternberg F, Moriggl R, Theurillat JP, Tichy B, Bystry V, Persson JL, Mathas S, Aberger F, Strobl B, Pospisilova S, Merkel O, Egger G, Lagger S, Kenner L.
    Mol Cancer; 2024 May 29; 23(1):114. PubMed ID: 38811984
    [Abstract] [Full Text] [Related]

  • 10. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
    Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP.
    Nature; 2010 Mar 18; 464(7287):374-9. PubMed ID: 20237562
    [Abstract] [Full Text] [Related]

  • 11. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.
    Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, Koochekpour S, Saleem M, Huang H, Lu J, Deng Y.
    Cell Rep; 2014 Sep 11; 8(5):1461-74. PubMed ID: 25176644
    [Abstract] [Full Text] [Related]

  • 12. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
    Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP.
    Nat Genet; 2013 Jul 11; 45(7):739-746. PubMed ID: 23727861
    [Abstract] [Full Text] [Related]

  • 13. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.
    Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS.
    Mol Cancer Res; 2010 Aug 11; 8(8):1126-41. PubMed ID: 20647331
    [Abstract] [Full Text] [Related]

  • 14. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
    Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB.
    Oncogene; 2012 Apr 12; 31(15):1949-62. PubMed ID: 21909130
    [Abstract] [Full Text] [Related]

  • 15. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
    González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP.
    Cancer Discov; 2014 Aug 12; 4(8):896-904. PubMed ID: 24866151
    [Abstract] [Full Text] [Related]

  • 16. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
    Wan W, Hou Y, Wang K, Cheng Y, Pu X, Ye X.
    Cell Death Dis; 2019 Mar 13; 10(3):248. PubMed ID: 30867411
    [Abstract] [Full Text] [Related]

  • 17. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.
    Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP.
    Cell; 2011 Jan 21; 144(2):187-99. PubMed ID: 21241890
    [Abstract] [Full Text] [Related]

  • 18. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
    Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA.
    PLoS Genet; 2009 Jul 21; 5(7):e1000542. PubMed ID: 19578399
    [Abstract] [Full Text] [Related]

  • 19. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J, Hooker E, Balog S, Zeng H, Johnson DT, He Y, Yu EJ, Wu H, Le V, Lee DH, Aldahl J, Gonzalgo ML, Sun Z.
    J Biol Chem; 2018 Dec 28; 293(52):20123-20136. PubMed ID: 30401749
    [Abstract] [Full Text] [Related]

  • 20. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN, Hao ZZ, Dong JT.
    Neoplasia; 2014 Nov 28; 16(11):883-99. PubMed ID: 25425963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.